- Home
- NIE vs PRTA Comparison
NIE vs PRTA Comparison
Compare NIE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- PRTA
- Stock Information
- Founded
- NIE 2007
- PRTA 2012
- Country
- NIE United States
- PRTA Ireland
- Employees
- NIE N/A
- PRTA N/A
- Industry
- NIE Investment Managers
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- PRTA Health Care
- Exchange
- NIE Nasdaq
- PRTA Nasdaq
- Market Cap
- NIE 694.9M
- PRTA 802.8M
- IPO Year
- NIE N/A
- PRTA N/A
- Fundamental
- Price
- NIE $23.68
- PRTA $11.87
- Analyst Decision
- NIE
- PRTA Buy
- Analyst Count
- NIE 0
- PRTA 7
- Target Price
- NIE N/A
- PRTA $57.67
- AVG Volume (30 Days)
- NIE 70.5K
- PRTA 501.9K
- Earning Date
- NIE 01-01-0001
- PRTA 02-13-2025
- Dividend Yield
- NIE 9.04%
- PRTA N/A
- EPS Growth
- NIE N/A
- PRTA N/A
- EPS
- NIE N/A
- PRTA N/A
- Revenue
- NIE N/A
- PRTA $133,350,000.00
- Revenue This Year
- NIE N/A
- PRTA $46.28
- Revenue Next Year
- NIE N/A
- PRTA N/A
- P/E Ratio
- NIE N/A
- PRTA N/A
- Revenue Growth
- NIE N/A
- PRTA N/A
- 52 Week Low
- NIE $18.61
- PRTA $11.96
- 52 Week High
- NIE $22.47
- PRTA $41.55
- Technical
- Relative Strength Index (RSI)
- NIE 37.69
- PRTA 43.50
- Support Level
- NIE $24.32
- PRTA $12.31
- Resistance Level
- NIE $24.77
- PRTA $14.28
- Average True Range (ATR)
- NIE 0.38
- PRTA 0.98
- MACD
- NIE -0.14
- PRTA 0.00
- Stochastic Oscillator
- NIE 0.40
- PRTA 33.73
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).